Bilcare Technologies has entered into agreement with global and domestic pharma companies such as MSD, Ranbaxy, Mankind and Panacea to offer its nanotechnology-based anti-counterfeit technology.

"We are working to implement this technology for the Delhi police. It is also being deployed in leading pharmaceutical and agrochemical companies in India," said Mohan Bhandari, MD, Bilcare.

Lupin Limited's US subsidiary, Lupin Pharmaceuticals, Inc has been able to receive the final authorization for the company's Abbreviated New Drug Application for its lamotrigine tablets, 25 mg, 100 mg, 150 mg and 200 mg strengths, from the US Food and Drug Administration.

A joint investigation by the BMJ and the Bureau of Investigative Journalism has revealed that the key scientists suggesting World Health Organization on planning for flu were paid by pharmaceutical firms. This advice by WHO led various Governments in the world to store antiviral drugs worth billions of dollars as global epidemic attentiveness plans. These stockpiling gave industry the profit worth $7bn.

Following the failure of its experimental cancer drug Recentin in treatment of colon cancer reported in a study on Friday, AstraZeneca has decided to terminate its further production.

It has removed the drug as the firstline product for the cancer cure.

The failure was received as a shock by a number of experts as well as the Company.

Abbott Laboratories has settled to purchase the domestic healthcare production of India's Piramal Healthcare Ltd., which is a leading generics corporation, for $3.72 billion, the companies stated on Friday.

The contract reflects the mounting international significance of generics as well as the increase of India's customer market for drugs.

A spokesperson for the Indian drug maker said Friday, From the U. S Food and Drug Administration, Dr. Reddy’s Laboratories has received approval, to sell generic immune system drug tacrolimus for organ transplants recipients.

Even as it lost money in California after state regulators forced it to delay premium increase of as much as 30 percent for thousands of customers who buy their own insurance, Well Point Inc said that earnings jumped 51 percent during the first three months of the year compared with the same time last year.